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Abstract
Mitochondrial transfer RNA (mt-tRNA) mutations have been reported to be associated with a variety of diseases. In a
previous paper that studied the mtDNA background effect on clinical expression of Leber’s hereditary optic neuropathy
(LHON) in 182 Chinese families with m.11778G.A, we found a strikingly high frequency (7/182) of m.593T.C in the
mitochondrially encoded tRNA phenylalanine (MT-TF) gene in unrelated LHON patients. To determine the potential role of
m.593T.C in LHON, we compared the frequency of this variant in 479 LHON patients with m.11778G.A, 843 patients with
clinical features of LHON but without the three known primary mutations, and 2374 Han Chinese from the general
populations. The frequency of m.593T.C was higher in LHON patients (14/479) than in suspected LHON subjects (12/843)
or in general controls (49/2374), but the difference was not statistically significant. The overall penetrance of LHON in
families with both m.11778G.A and m.593T.C (44.6%) was also substantially higher than that of families with only
m.11778G.A (32.9%) (P=0.083). Secondary structure prediction of the MT-TF gene with the wild type or m.593T.C showed
that this nucleotide change decreases the free energy. Electrophoretic mobility of the MT-TF genes with the wild type or
m.593T.C transcribed in vitro further confirmed the change of secondary structure in the presence of this variant. Although
our results could suggest a modest synergistic effect of variant m.593T.C on the LHON causing mutation m.11778G.A, the
lack of statistical significance probably due to the relatively small sample size analyzed, makes necessary more studies to
confirm this effect.
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Introduction
Leber’s hereditary optic neuropathy (LHON; MIM 535000) is
characterized by acute or sub-acute visual failure in young adults
and is the first mitochondrial disorder described [1,2]. It later
turned out that in over 95% of LHON cases the disease was
caused by the presence of one of three primary mutations that
were located in the MT-ND4 gene (m.11778G.A), the MT-ND1
gene (m.3460G.A), and the MT-ND6 gene (m.14484T.C),
respectively. Incomplete penetrance and gender bias are two
features of the clinical expression of LHON, but the exact
underlying mechanisms for the onset of these two features have
not been well resolved. Nuclear genes, mtDNA background/
haplogroups, and environmental factors have been shown or
suggested to affect the penetrance of LHON [1,2].
Human mitochondrial transfer RNAs (mt-tRNAs) are essen-
tial for translation of the thirteen mtDNA encoded protein
subunits. Twenty-two mt-tRNAs are transcribed from mtDNA,
with one corresponding to one amino acid (excluding leucine
and serine), and cannot be imported into mitochondria from the
cytoplasm in human [3]. Mutations in mt-tRNAs, either in a
sporadic status or maternally inherited, constitute the most
common mtDNA alterations that are associated with human
disorders [4]. Polymorphisms in mt-tRNAs are also common in
general populations. Hitherto, more than 100 mt-tRNA
mutations have been reported to be associated with mitochon-
drial disorders [5]. Among them, m.3243A.Gi nt h eMT-TL1
[mitochondrially encoded tRNA leucine 1 (UUA/G)] gene is
one of the most common mt-tRNA mutations that cause a
variety of human diseases, such as diabetes, mitochondrial
myopathy, MELAS (mitochondrial myopathy, encephalopathy,
lactic acidosis, and stroke-like episodes) [6,7]. The pathogenic
mutations in mt-tRNA can alter the secondary structure or
change one highly conserved base to another base, abolish the
tertiary structure and lead to dysfunction [5,8,9]. Mutations in
mt-tRNAs affect biogenesis and function of mt-tRNAs via a
large variety of mechanisms, including transcription, maturation,
posttranscriptional modification, structure, stability, aminoacyla-
tion, capability of binding to elongation factor EF-Tu, and
codon reading [10].
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26511In a recent study we showed that mtDNA haplogroups M7b192
and M8a affected the clinical expression of LHON in Chinese
families with m.11778G.A, with an increased risk for M7b192 and
a decreased risk for M8a [11]. This pattern was different from that
of western European LHON patients, in which other haplogroups
appear to contribute to the increased risk of visual failure in families
with m.11778G.A (haplogroup J2), m.14484T.C (haplogroup
J1), or m.3460G.A (haplogroup K), whereas haplogroup H had a
protective effect for families with m.11778G.A [12]. Intriguingly,
we found that variant m.593T.C in tRNA
phe (MT-TF) had a
relatively high occurrence in Chinese LHON patients (7/182) [11].
The distribution frequency of m.593T.C in Chinese LHON
patients with m.11778G.A was by an order of magnitude higher
than in East Asian populations (4/1262, http://www.phylotree.
org/; Table S1). In order to determine whether an association of
m.593T.C with LHON could be predicted, we have systematically
screened m.593T.C in 479 LHON patients with m.11778G.A
(including 175 mtDNAs from the earlier study [11]), 843 patients
suspected with LHON, and 2374 Han Chinese from the general
populations without any visual disorder. Complete mtDNA
sequencing of probands with both m.593T.C and m.11778G.A
and in vitro transcribed assay were further performed to understand
the potential interaction between the variant and LHON. Our
results suggest that m.593T.C in LHON families may have a
potentially synergistic effect with m.11778G.A.
Materials and Methods
Ethics statement
Written informed consents conforming to the tenets of the
Declaration of Helsinki were obtained from each participant prior
to this study. The institutional review boards of the Zhongshan
Ophthalmic Center and the Kunming Institute of Zoology
approved this study.
Patients
We recently launched a comprehensive survey for mtDNA
mutations in Chinese patients with LHON or suspected LHON
and eventually provided the largest patient sample collection in
China to date. Part of this patient cohort was characterized in a
series of previous publications [11,13–18]. Among this cohort, 479
LHON patients harbored m.11778G.A (including 175 mtDNAs
from the earlier study [11]), 843 patients had clinical features of
LHON but without the three known primary mutations and were
termed suspected LHON patients. All these patients were collected
at the Pediatric and Genetic Clinic of the Eye Hospital,
Zhongshan Ophthalmic Center or other local ophthalmic centers.
A total of 2374 Han Chinese who had no ophthalmologic disease
were collected from Yunan and Hunan Province and were
screened for the presence of m.593T.C. Because the matrilineal
structure of patients with suspected LHON was similar to that of
the general population (authors’ unpublished data), we therefore
took the 843 suspected LHON patients collected from different
provinces in China as another control population for comparison.
We followed our previous study [14] to define as sporadic any
proband from a family with only one patient (according to the
accessible pedigree information) or with unclear family history. In
particular, this definition for sporadic case also includes the family
with several asymptomatic carriers of m.11778G.A but with only
one affected member (viz. the proband).
mtDNA sequence analysis
Total genomic DNA was isolated from blood using a standard
phenol/chloroform method. The mtDNA control region sequences
and complete mtDNA genomes were amplified and sequenced
using a modified method as described in our previous studies
[11,19]. Sequences were handled by the DNASTAR program
(DNASTAR Inc., Madison, WI, USA). Sequence variation was
scored relative to the revised Cambridge Reference Sequence
(rCRS) [20]. We classified the LHON mtDNAs using PhyloTree
Build 11 (http://www.phylotree.org; 7 Feb 2011) [21] and
MitoTool (http://www.mitotool.org) [22]. mtDNA variants in each
complete mtDNA were scored as novel or reported according to an
exhaustive database search following previous guidelines [23]. Five
reported mtDNA sequences (GenBank accession nos. GQ301863
[24], AF347007 [25], AY255137 [26], EF153821 [27], and
AP008571 [28]) from East Asian populations with m.593T.C
were considered for comparison. Sequence variation of each
mtDNA relative to the rCRS was presented in an mtDNA tree,
following the same procedure as in our previous studies [11,29].
Evolutionary conservation analysis for m.593T.C mutation was
performed using the same approach as in our previous study [19].
The potential relationship among these mtDNAs harboring
m.593T.C that were identified from the LHON patients,
suspected LHON patients and Han Chinese from the general
populations was presented in a network, following the approach
described in Bandelt et al. [30].
Site-directed mutagenesis and in vitro transcription of
the MT-TF gene
The wild type human mt-tRNA
Phe plasmid and two mutant
plasmids (G7A hmt-tRNA
Phe [bearing m.583G.A] and G34A
hmt-tRNA
Phe [bearing m.611G.A]) were kind gifts from Dr.
Michael Ibba’s lab [9]. Site-directed mutagenesis was performed
to obtain mt-tRNA
Phe mutant plasmid bearing m.593T.C. The
mutant primers were T593C-F (GTTTATGTAGCTTACCCC-
CTCAAAGCAATACACT) and T593C-R (AGTGTATTGC-
TTTGAGGGGGTAAGCTACATAAAC). PCR reaction was
performed in a volume of 50 mL reaction mixture containing
5 mL1 0 6Cloned Pfu DNA polymerase reaction buffer (containing
2m MM g
2+), 2.5 units of PfuTurb hotstart DNA polymerase
(Stratagene), 400 mM of each dNTP, 0.1 mM of each primer, and
50 ng wild type mt-tRNA
Phe plasmid DNA. PCR amplification
cycles were composed of one denaturation cycle at 94uC for
5 min, 30 cycles of 94uC for 30 s, 65uC for 40 s and 72uC for
4 min, one final extension cycle at 72uC for 10 min.
The PCR product was transformed into DH5a competent cells
(Tiangen Bio CO. LTD., Beijing, China) and the plasmids were
amplified. We purified the plasmids by using TIANprep Mini
Plasmid Kit (Tiangen Bio CO. LTD., Beijing, China). The wild
type mt-tRNA
Phe and mutant mt-tRNA
Phe plasmids were
transcribed in vitro by using mMESSAGE mMACHINE Kit
(Ambion, Inc) following the manufacture’s instruction.
Analysis of MT-TF secondary structure
The secondary structures of the MT-TF gene with or without
m.593T.C were analyzed by the MFOLD program (http://
mobyle.pasteur.fr/cgi-bin/portal.py) [31] to predict the potential
change caused by the nucleotide alteration. Native and denaturing
gel electrophoresis were used to detect the structure change of the
MT-TF gene caused by m.593T.C. The two reported pathogenic
mutations (m.583G.A [32] and m.611G.A [33]) in the MT-TF
gene and the wild-type MT-TF gene were used as positive controls
and negative control [9], respectively. The transcribed MT-TF
RNA was separated by PAGE following the same condition
described by Ling et al. [9]. In brief, native gel was comprised of
16TBE (89 mM Tris-boric/2 mM Na2EDTA, pH 8.3) and 12%
acrylamide-bis, and was run at 50 V at 4uC for 11 hours.
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bis, and was run at 200 V at room temperature for 1 hour.
Statistical analysis
Two tailed Fisher’s exact test was used to evaluate the difference
of m.593T.C frequency in LHON samples with m.11778G.A
and suspected LHON samples or normal controls. The penetrance
rates of LHON in pedigrees with LHON family history and
m.11778G.A in the presence or absence of m.593T.C were also
quantified. A P value less than 0.05 was regarded as statistically
significant.
Results
Clinical features of LHON families with both
m.11778G.A and m.593T.C
A total of 14 LHON patients from six difference provinces who
had both m.11778G.A and m.593T.C were distilled from the
entire patients cohort. Among them, seven patients with a family
history (Le51, Le251, Le394, Le549, Le554, Le953 and Le1120)
were reported in our previous study [11], seven sporadic patients
were newly included in this study (Table 1). The occurrence of
m.593T.C in LHON patients with m.11778G.A (2.92%; 14/
479) was two-fold higher than that of suspected LHON samples
(1.42%; 12/843), but statistical analysis only showed a P value
marginally close to 0.05 (P=0.066). The higher frequency of
m.593T.C in LHON patients with m.11778G.A is mainly due
to the 175 reported matrilines from pedigrees with a family history
of LHON [11] (we counted one proband per family). In fact, when
these mtDNAs were excluded we found that the frequency of
m.593T.C in the remaining 304 LHON samples (2.3%; 7/304)
was close to that of Han Chinese from the general populations
(2.06%; 49/2374). Because the majority of these 304 mtDNAs
were from patients with sporadic LHON, it is most likely that
m.593T.C was only enriched in patients from pedigrees with a
family history of LHON. Note that we grouped these patients from
a family with only one patient (according to the accessible pedigree
information) or with unclear family history as sporadic in this
study. This working definition may cause a potential bias for the
above comparison.
The penetrance of LHON in the seven pedigrees that presented
a family history and harbored both m.11778G.A and
m.593T.C was 44.6% (25/56) (Table 1), much higher than that
of families with only m.11778G.A (32.9%, 594/1803) [11].
However, this difference was not significant either (P=0.083),
partially because of the relatively small sample size of families with
both m.11778G.A and m.593T.C.
mtDNA sequence variation and evolutionary analysis
We sequenced the entire mtDNA genomes of five LHON
patients (Le51, Le53, Le840, Le1192, and Le1407; GenBank
accession numbers JF896797–JF896801) and the mtDNA control
region sequences of three probands (Le682, Le878 and Le1561)
with both m.11778G.A and m.593T.C (Table 1). Sequence
variation (in either the complete mtDNA genome or in the control
region) of the remaining six LHON patients was reported in our
previous study [11]. According to mtDNA sequence variation
(Table S2), patients Le682, Le878 and Le1561 belonged to
haplogroup G1c. Analysis of the five complete mtDNA sequences
indicated that these lineages belonged to haplogroups C7a2 (newly
defined here based on the motif 16189-2232+A, Le51), M7b19294
(Le53), D4g2 (Le840), and B5a1c1 (newly defined here based on
the motif 593-5237-10325-10523, Le1192 and Le1407), respec-
tively (Fig. 1). Besides m.11778G.A, m.593T.C and the
haplogroup-specific variants in each sample, there were several
private variants in each lineage (Table 2). Le51 harbored five
private variants (m.6249G.A and m.7007C.T in the MT-CO1
gene, m.7990C.T in the MT-CO2 gene, and m.16183A.C and
m.16519T.C in the control region). Among these, only variant
m.6249G.A (p.A116T) causes an amino acid change. Le53
owned five private variants (m.1694T.C in the MT-RNR2 gene,
the synonymous changes m.4137C.T in the MT-ND1 gene and
m.11659C.T in the MT-ND4 gene, and m.16189T.C and
m.16519T.C in the control region). Le840 had five private
variants that were located in the MT-ND2 (m.4959G.A,
p.A164T), MT-ND4 (m.11935T.C), MT-ND5 (m.12972A.G)
Table 1. Detailed information of LHON probands with m.593T.C.
Sample Haplogroup Location Family history
No. of affected
family members
Total number of
family members
Penetrance
(%)
Le53 M7b19294 Guangdong No - - -
Le682 G1c Guangdong No - - -
Le840 D4g2 Jiangxi No - - -
Le878 G1c Jiangxi No - - -
Le1192 B5a1c1 Guangdong No - - -
Le1407 B5a1c1 Hunan No - - -
Le1561 G1c Guangdong No - - -
Le51
a C7a2 Guangdong Yes 5 8 62.5
Le251
a Z Henan Yes 5 5 100.0
Le394
a D4 Hebei Yes 4 14 28.6
Le549
a M10a2 Anhui Yes 4 10 40.0
Le554
a G1c Henan Yes 2 9 22.2
Le953
a G1c Hebei Yes 3 5 60.0
Le1120
a D4g2 Jiangxi Yes 2 5 40.0
aThese seven LHON families were reported in our previous study [11].
doi:10.1371/journal.pone.0026511.t001
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Le1192 also had several private variants including three
synonymous changes in the coding region (m.5237G.Ai n
the MT-ND2 gene, m.10325G.Ai nt h eMT-ND3 gene,
m.10523A.Gi nMT-ND4L gene) and six variants in the
control region (m.64C.T, m.523-524d, m.16183A.C,
m.16189T.C, m.16262C.T and m.16519T.C). There was
no novel mtDNA variant [23] in these lineages. None of the three
Figure 1. Classification tree of 12 complete mtDNA sequences, plus the revised Cambridge reference sequence (rCRS) [20]. Six
Chinese LHON mtDNAs (including Le953 [FJ198218] [11]) had both m.593T.C and m.11778G.A. Five reported mtDNAs (GQ301863 [24], AF347007
[25], AY255137 [26], EF153821 [27], and AP008571 [28]) harbored m.593T.C. One mtDNA (EF429138 [43]) without either variant was used to define
the novel haplogroup C7a2. The length polymorphisms of the C-tracts in region 303–309 were disregarded. The order of mutations on each
uninterrupted branch segment is arbitrary. Recurrent mutations are underlined. The synonymous and non-synonymous coding-region variants in the
mtDNA sequences are denoted by ‘‘/s’’ and ‘‘/ns’’, respectively. Variants in the ribosomal RNA genes and tRNA genes are denoted by ‘‘/r’’ and ‘‘/t’’,
respectively.
doi:10.1371/journal.pone.0026511.g001
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were identified in the above patients was conserved, and all of them
were reported in general populations, suggesting that these variants
were most likely polymorphisms (Table 2). Similarly, the thymine at
the 17th position (i.e., m.593T) of the MT-TF gene, which is located
in the dihydrouracil loop (D loop) of tRNA
Phe, was not conserved in
eight vertebrate species (Fig. 2).
We constructed a network for all the 75 mtDNAs with
m.593T.C that were identified from the LHON patients
(n=14), suspected LHON patients (n=12) and Han Chinese
from the general populations (n=49). It is evident that
m.593T.C occurred multiple times in different haplogroups,
and it defined haplogroups G1c and B5a1c1 (Fig. 3 and Table S2).
MT-TF gene secondary structure analysis
The free energy is a criterion for judging the stability of RNA
structure in vivo; most of the RNA secondary structure predictions
are based on the free energy minimization method [32,34]. The
RNA secondary structure can be predicted more accurately by
thermodynamics determined from the primary sequence without
information of tertiary contacts or protein interaction; the lower
the free energy the more stable the structure is, but this is not an
absolute fact because of biological complexity [35]. Alteration of
the MT-TF gene secondary structure in the presence of
m.593T.C is shown in Figure 4. The predicted structure of the
wild type MT-TF gene has a free energy (DG) value of 210.94
(Fig. 4A). There are two predicted structures of the MT-TF gene
bearing variant m.593T.C. The first type is similar to that of the
wild type gene, whereas the second one has a lower free energy
value of 211.4 and a reduced size of the dihydrouracil loop (D
loop) (Fig. 4B). We speculate that the shift of two predicted
structures of the MT-TF gene in vivo in the presence of m.593T.C
might slightly impair its function, despite the fact that the second
predicted structure had a lower free energy (which means higher
stability).
The electrophoretic mobility of the secondary structure of the
wild type and mutant MT-TF genes transcribed in vitro showed that
variant m.593T.C affected the migration of mutant tRNA
Phe
compared to the wild type on the native gel. However, this structure
change disappeared when we separated the transcribed RNAs on a
denaturinggel(Fig.5).Theobservedpatternwasingood agreement
with the predicted change of the secondary structure of the MT-TF
gene in the presence of m.593T.C.
Discussion
Mitochondrial tRNAs played an important role in mtDNA
translation because the nuclear tRNA could not be transported
from cytoplasm into mitochondria in human [3,36]. The
mutations occurred in mt-tRNAs can change the secondary
structure and alter the tertiary structure, further affect the
translation of mtDNA encoded genes. Many pathogenic mutations
in mt-tRNA genes have been reported to be associated with
human diseases, despite that defining the pathogenicity of mt-
tRNA mutations are not easy [4,5,8,10,37]. In this study, we
aimed to elucidate the role of variant m.593T.C in the MT-TF
gene in LHON patients. By screening m.593T.C in 479 LHON
cases with m.11778G.A (including 175 cases reported in our
earlier study [11]), 843 suspected LHON samples without the
three known primary mutations, as well as 2374 general controls,
we observed a higher frequency of m.593T.C in LHON patients
with m.11778G.A (2.92%; 14/479) than in suspected LHON
patients (1.42%; 12/843) or Han Chinese from the general
populations (2.06%; 49/2374), despite that the difference was not
statistically significant. However, when we focused on 182
matrilines from 182 Chinese families (including 7 families analyzed
in other studies; Ref. [11] and see references therein; we counted
only one affected member per family) with m.11778G.A and a
family history of LHON [11], the frequency of m.593T.C
(3.85%; 7/182) was substantially higher than those of suspected
LHON patients and Han Chinese from the general populations.
This suggests that m.593T.C was only enriched in pedigrees with
m.11778G.A and a family history of LHON, but not in sporadic
LHON patients with m.11778G.A.
In the presence of mtDNA subhaplogroups defined by
m.593T.C (among other variants), hidden populationsubstructure
Table 2. Private non-synonymous and mt-tRNA variants in Chinese LHON mtDNAs with m.11778G.A and m.593T.C.
Family
a Haplogroup
Nucleotide variant
(Amino acid change) Gene Conservation
c
Reported
(Population context)
b
Reported
(Disease context)
b
Haplogroup specific
variant
d
Le51 C7a2 m.6249G.A (p.A116T) MT-COI No Yes Yes L0d2c, P7
Le53 M7b19294 m. 1694T.C MT-RNR2 No Yes No L4b2a2
Le840 D4g2 m. 4959G.A (p.A164T) MT-ND2 No Yes Yes D4h3a4, D4e1a2a, T1a2
aThe complete mtDNA complete genomes of Le1192 and Le1407 contained no private non-synonymous and mt-tRNA variants and were not included.
bThe search was performed on April 18, 2011 following the same strategy described earlier [23] (e.g. both ‘G6249A mtDNA’ and ‘m.6249G.A mtDNA’ were queried).
cThe conservation analysis was performed by comparing Homo sapiens mtDNA (GenBank accession No. J01415) to 43 different vertebrate species by using the MitoTool
(http://www.mitotool.org) [22].
dThe column ‘‘Haplogroup specific variant’’ refers to the presence of the corresponding variants in the world mtDNA phylogeny displayed at http://www.phylotree.org/
tree/main.htm (mtDNA tree Build 11; 7 Feb 2011) [21]. In round brackets we indicate the haplogroup status as it defined in that tree.
doi:10.1371/journal.pone.0026511.t002
Figure 2. Evolutionary conservation analysis for mitochondrial
tRNA
Phe variant m.593T.C. The mt-tRNA sequence with m.593T.C
is compared to the revised Cambridge reference sequence (rCRS; Homo
sapiens, GenBank accession number J01415) and those derived from
seven different vertebrate species: gorilla (Gorilla gorilla NC_001645),
mouse (Mus musculus AY466499), dog (Canis familiaris DQ480502),
cattle (Bos taurus AY526085), horse (Equus caballus EF597513), zebrafish
(Danio rerio NC_002333), and frog (Rana nigromaculata AB043889).
doi:10.1371/journal.pone.0026511.g002
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one of the characteristic motifs of both haplogroups G1c and
B5a1c1 (Fig. 1), we therefore excluded those samples with
m.593T.C belonging to these two haplogroups, to minimize the
potentially regional effect on the distribution of m.593T.Ci n
our samples. After removing these samples, we found a substan-
tially higher frequency m.593T.C in LHON patients with
m.11778G.A (1.48%; 7/472) than in suspected LHON patients
(0.60%; 5/836) or in Han Chinese from the general populations
(0.30%; 7/2332). Another potential effect could in principle be
caused by haplogroup M7b192 which was shown to increase the risk
of visual loss in the presence of m 11778G.A [11]. However, there
was only a single LHON sample from this haplogroup in our study
bearing m.593T.C, so that this haplogroup could not have biased
our present results.
In concordance with the increased frequency of m.593T.Ci n
LHON patients with m.11778G.A, we found that the seven
LHON pedigrees with m.11778G.A, m.593T.C and a family
history of the disease had a higher penetrance (44.6%) than that of
pedigrees with only m.11778G.A (32.9%), albeit this difference
was not statistically significant. This is another piece of evidence
that the relatively high occurrence of m.593T.C among patients
with a family history of LHON would be unlikely to be a mere
chance event. More pedigrees with both m.11778G.A and
m.593T.C are essential to further validate this pattern.
In a recent study by Kaewsutthi et al. [38], haplogroup B5a1
was suggested to increase risk of visual loss in LHON patients with
m.11778G.A from Thailand. However, only three of the
reported 10 B5a1 LHON lineages shared 10325 with our newly
defined B5a1c. The relatively lower frequency of B5a in LHON
patients (0.4%) than those of suspected LHON patients (0.6%) and
Han Chinese from general populations (1.0%) indicates that this
haplogroup is unlikely to affect LHON in Chinese.
Recent evaluation of mtDNA mutation rate showed that
position 593 had a modest mutation rate [39] and is not
evolutionarily conserved in vertebrate species (Fig. 2). Analysis of
Figure 3. Network of 75 mtDNAs with m.593T.C that were identified in 479 LHON patients, 843 suspected LHON patients and 2374
Han Chinese from the general populations. Each circle represents an mtDNA haplotype, with its area being proportional to the frequency of the
haplotype. The order of mutations on each uninterrupted branch section is arbitrary. Recurrent mutations are underlined. The length polymorphisms
of the C-tracts in regions 16183–16192 and 303–309 and of AC repeats in region 515–524 in the mtDNA control region were disregarded. All
individuals contain variants 16519-73-263-315+C-750 relative to the revised Cambridge reference sequence (rCRS) [20]. The current classification
within M7b will need some revision in the future in regard to the positions 16189 and 16192, so that the exact number of 593 mutational events is
left undetermined for the time being.
doi:10.1371/journal.pone.0026511.g003
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reported Le953 [11]) revealed no previously unreported private
variants (Table 2 and Fig. 1). It is therefore conceivable that the
relatively higher penentrance of LHON in those families with
m.593T.C and m.11778G.A was not caused by the private
variants in each lineage but rather by the synergistic effect of
m.593T.C in the presence of m.11778G.A.
Despite that evolutionary analysis of m.593T.C showed that
this position is not conserved, secondary structure prediction and
in vitro experiment of the MT-TF gene demonstrated that the
mutant allele changes the secondary structure in vitro (Figs. 4 and
5). It is possible that this structure alteration affects the efficiency of
cognition between the phenylalanyl-tRNA synthetase (PheRS) and
tRNA
Phe and protein translation. Some pathogenic mutations in
the MT-TF gene, such as m.582T.C and m.583G.A, can
change the secondary structure of the MT-TF gene and decrease
the aminoacylation activity after transcribed in vitro [9]. Two
classes of aminoacyl tRNA synthetase (I and II) with different
editing sites have been identified [40]. The PheRS belongs to class
II and its editing site is located in the B3/B4 domain [41]. mt-
tRNA
Phe with m.593T.C may not be cognized by the PheRS
because this variant changed the secondary tertiary structure of
the MT-TF gene. Moreover, editing activity of the PheRS
decreased during the evolution of mitochondrial PheRS, and the
decreased cognitional activity between the PheRS and tRNA
Phe
may affect the translational quality control [42]. The mutant
tRNA
Phe caused by m.593T.C may decrease the cognitional
activity to the PheRS and further enhance the clinical expression
of LHON in the presence of m.11778G.A. Further functional
assays, e.g. a test for the translation efficiency in cybrid cells with
m.11778G.A mtDNA carrying or not this variant, are essential
for validating our speculation and for understanding the potential
mechanism under the presumed synergistic effect of m.593T.C
with m.11778G.A.
In summary, we found a higher distribution frequency of
m.593T.C in LHON patients with m.11778G.A than in the
control populations, though the difference was not statistically
significant. Presence of m.593T.C increased the penetrance of
LHON in families with m.11778G.A, albeit the difference also
did not reach a statistically significant level (probably due to the
limited number of samples). Despite that the position 593 was not
evolutionarily conserved and had a modest mutation rate in
human mtDNA, it altered the secondary structure of the MT-TF
gene as demonstrated by an in vitro transcribed assay. All these
lines of evidence suggest that m.593T.C may enact a modest (if
any) synergistic effect with m.11778G.A in LHON. More studies
are needed to validate our current findings and to unveil the effect
of the MT-TF gene variant on the pathogenicity of mutation
m.11778G.A.
Supporting Information
Table S1 Presence of variant m.593T.C in 1262 East Asian
mtDNAs from the PhyloTree database.
(DOC)
Figure 4. Predicted secondary structure of the wild type human MT-TF gene (A) and the mutant harboring m.593T.C (B). Position 593
was marked by an arrow. DG means the free energy.
doi:10.1371/journal.pone.0026511.g004
Figure 5. Native and denaturing gels showing the migration of
RNAs of the wild type MT-TF gene and mutants. Electrophoretic
mobility is from top to bottom. The mutant tRNA
Phe plasmids with
m.583G.A and m.611G.A are gifts from Prof. Michael Ibba’s lab and
were named as G7A hmt-tRNA
Phe and G34A hmt-tRNA
Phe in their study
[9], respectively.
doi:10.1371/journal.pone.0026511.g005
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